This suggests that PARP inhibitors could be expanded to other indications, including BRCA-mutated prostate cancer and those harbouring mutations in DDR proteins such as ataxia-telangiectasia mutated (ATM) [12–15]. The gene discussed is ATM; the disease is prostate carcinoma.